<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972023000300026</article-id>
<article-id pub-id-type="doi">10.26445/08.03.3</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[COVID-19 y Enfermedades Autoinmunes Sistémicas ¿cuál es la relación y sus consecuencias?]]></article-title>
<article-title xml:lang="en"><![CDATA[COVID-19 and Systemic Autoimmune Diseases, what is the relationship and its consequences?]]></article-title>
<article-title xml:lang="pt"><![CDATA[COVID-19 e Doenças Autoimunes Sistêmicas, qual a relação e suas consequências?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Graña]]></surname>
<given-names><![CDATA[Diego]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[O&#8217;Neil]]></surname>
<given-names><![CDATA[Florencia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gaudiano]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[Alvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Spiess]]></surname>
<given-names><![CDATA[Cecilia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Turnes]]></surname>
<given-names><![CDATA[Belen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Unidad de Enfermedades Autoinmunes. Unidad Académica Médica 2. Hospital Pasteur]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2023</year>
</pub-date>
<volume>8</volume>
<numero>3</numero>
<fpage>26</fpage>
<lpage>34</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972023000300026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972023000300026&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972023000300026&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  Los pacientes portadores de enfermedades autoinmunes sistemas constituyen una población vulnerable para el desarrollo de infección por COVID-19. Objetivo: Determinar la frecuencia de infección por COVID-19 en los pacientes asistidos en la policlínica, su severidad y su relación con el tratamiento inmunosupresor. Conocer el número de brotes y la tasa de vacunación de nuestra población.  Metodología:  Estudio transversal de pacientes asistidos en una unidad de enfermedades autoinmunes sistémicas en el período abril 2020-julio 2021.  Resultados:  Se analizaron 59 pacientes, 19 tuvieron brote de la enfermedad en el último año. 12 tuvieron infección por COVID-19, uno ingresó a cuidados moderados. La mediana de edad de los pacientes infectados fue de 35 años. 55 recibieron vacunación completa.  Conclusiones:  No se encontró una asociación entre la infección por COVID-19 y brotes de la enfermedad así como tampoco una mayor tasa de hospitalización ni muerte. Los pacientes con Lupus fueron los más vulnerables. La tasa de controles media (presencial/telefónica) fue alta para la totalidad de la población así como la tasa de vacunación.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Patients with autoimmune system diseases constitute a vulnerable population for the development of SARS-CoV-2 infection.  Objectives:  To determine the incidence of SARS-CoV-2 infection in patients seen at the polyclinic.  Methodology:  Cross-sectional study patients assisted in an autoinmune disease center in the period April 2020-July 2021.  Results:  59 patients were analyzed, 19 had flares of the disease in the last year. 12 had SARS CoV-2 infection, 1 was admitted to moderate care. The median age of infected patients was 35 years. 55 received full vaccination.  Conclusions:  No association was found between COVID-19 infection and diseases flares as well as an increased rate of hospitalization or death. Lupus patients were the most vulnerable. The controls rate (face-to-face/telephone) was high for the entire population as well as the vaccination rate.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  Pacientes com doenças autoimunes constituem uma população vulnerável ao desenvolvimento da infecção por COVID-19.  Objetivo:  Determinar a frequência da infecção por COVID-19 em pacientes atendidos na policlínica, sua gravidade e sua relação com o tratamento imunossupressor. Conheça o número de surtos e a taxa de vacinação da nossa população.  Metodologia:  Estudo transversal. Apresenta 59 pacientes atendidos em unidade EAS no período de abril de 2020 a julho de 2021.  Resultados:  Foram analisados &#8203;&#8203;59 pacientes, 19 tiveram surto da doença no último ano. 12 tiveram infecção por COVID-19, 1 foi internado em cuidados moderados. A idade média dos pacientes infectados foi de 35 anos. 55 receberam vacinação completa.  Conclusões:  não foi encontrada associação entre infecção por covid-19 e surtos da doença, nem maior taxa de hospitalização ou morte. Pacientes com lúpus eram os mais vulneráveis. A taxa média de controlo (presencial/telefone) foi elevada para toda a população, bem como a taxa de vacinação.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[COVID]]></kwd>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[Enfermedades autoinmunes]]></kwd>
<kwd lng="es"><![CDATA[Inmunosupresores]]></kwd>
<kwd lng="es"><![CDATA[Brotes]]></kwd>
<kwd lng="es"><![CDATA[Vacunas.]]></kwd>
<kwd lng="en"><![CDATA[COVID]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[Autoinmune disease]]></kwd>
<kwd lng="en"><![CDATA[Inmunosuppressive therapy]]></kwd>
<kwd lng="en"><![CDATA[Flares]]></kwd>
<kwd lng="en"><![CDATA[Vaccines.]]></kwd>
<kwd lng="pt"><![CDATA[COVID]]></kwd>
<kwd lng="pt"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="pt"><![CDATA[Doenças autoimunes]]></kwd>
<kwd lng="pt"><![CDATA[Imunossupressores]]></kwd>
<kwd lng="pt"><![CDATA[Brotos]]></kwd>
<kwd lng="pt"><![CDATA[Vacinas.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strangfeld]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schäfer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gianfrancesco]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Lawson-Tovey]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Liew]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Ljung]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 Global Rheumatology Alliance Factors associated19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2021</year>
<volume>80</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>930-42</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Consani Fernández]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Díaz Cuña]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández Rey]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rostán Sellanes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Maciel Oleggini]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Facal Castro]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infections in systemic autoimmune diseases]]></article-title>
<source><![CDATA[Reumatol Clin (Engl Ed)]]></source>
<year>2020</year>
<page-range>S1699-258X</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muñoz-Grajales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto Peñaranda]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Velásquez Franco]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez Hernández]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo Escobar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complicaciones infecciosas en lupus eritematoso sistémico]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2013</year>
<volume>20</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>141-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Enberg]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn ChM]]></surname>
</name>
<name>
<surname><![CDATA[Goity]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Villalón]]></surname>
<given-names><![CDATA[SMV]]></given-names>
</name>
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones en pacientes con lupus eritematoso sistémico]]></article-title>
<source><![CDATA[Rev Med Chil]]></source>
<year>2009</year>
<volume>137</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1367-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vega Miranda]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto Peñaranda]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz Grajales]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Márquez Hernández]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Padilla]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infecciones en pacientes con artritis reumatoidea: medicamentos moduladores de la respuesta bilógica vs fármacos modificadores de la enfermedad Seguimiento a un año]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2013</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-34</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zavala-Flores]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Salcedo-Matienzo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berrocal Kasay]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Covid-19 y enfermedades autoinmunes población con alto riesgo para desarrollar enfermedad severa?]]></article-title>
<source><![CDATA[Acta Med perú]]></source>
<year>2020</year>
<volume>37</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>407-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sparks]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[ZS]]></given-names>
</name>
<name>
<surname><![CDATA[Seet]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gianfrancesco]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Izadi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hyrich]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis Results from the COVID-19 Global Rheumatology Alliance physician registry]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2021</year>
<volume>80</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1137-46</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gaudiano]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Botta]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Graña]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Goñi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedades autoinmunes sistémicas y tuberculosis: una mala asociación]]></article-title>
<source><![CDATA[Rev Urug Med Int]]></source>
<year>2017</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zimba]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Gasparyan]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 and the clinical course of rheumatic manifestations]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2021</year>
<volume>40</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2611-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gianfrancesco]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hyrich]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Adely]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Carmona]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Danila]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Gossec]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease data from the COVID-19 Global Rheumatology Alliance physician-reported registry]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<volume>79</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>859-66</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cairoli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoimmune diseases and vaccines against COVID-19 Decision making in uncertain scenarios]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2021</year>
<volume>157</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rondaan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Heijstek]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Agmon-Levin]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[van Assen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bijl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2020</year>
<volume>79</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-52</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hyrich]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatic disease and COVID-19 epidemiology and outcomes. Nature reviews]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2021</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>71-2</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misra]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gasparyan]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Zimba]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rheumatologists&amp;apos; perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2020</year>
<volume>39</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2055-62</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Narváez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Graña]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Viera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Baccelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación entre el uso de glucocorticoides y el daño crónico en Lupus Eritematoso Sistémico: una asociación precoz y nociva. Estudio exploratorio]]></article-title>
<source><![CDATA[Rev Urug Med Int]]></source>
<year>2021</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>14-23</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Danza]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Graña]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Silveira]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rebella]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prednisone and long-term damage in systemic lupus erythematosus Which is the threshold dose? A pilot study]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2022</year>
<volume>31</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>880-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Sawalha]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[COVID-19 and autoimmune diseases]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2021</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-62</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Furer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Eviatar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zisman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Peleg]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Paran]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Levartovsky]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population a multicentre study]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2021</year>
<volume>80</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1330-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murthy]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Wodi]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Bernstein]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ault]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommended Adult Immunization Schedule, United States, 2022]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2022</year>
<volume>175</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>432-43</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Velikova]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Georgiev]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2021</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>509-18</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
